# Clinical Trial: NCT_TEST_001

## Study Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Investigational Drug XYZ in Patients with Type 2 Diabetes Mellitus

## Protocol Version
Version 1.0 - January 2024

## Sponsor
Test Pharmaceutical Company

## Study Phase
Phase 3

## Target Condition
Type 2 Diabetes Mellitus (T2DM)

---

## INCLUSION CRITERIA

Patients must meet ALL of the following criteria to be eligible:

1. **Age Requirement**
   - Age 18-75 years at the time of informed consent

2. **Diabetes Diagnosis**
   - Documented diagnosis of Type 2 Diabetes Mellitus according to ADA criteria
   - Duration of diabetes ≥6 months prior to screening

3. **Glycemic Control**
   - HbA1c between 7.0% and 10.0% (inclusive) at screening visit
   - HbA1c measurement within 4 weeks of randomization

4. **Background Therapy**
   - Currently on stable metformin therapy (≥1000mg/day) for at least 3 months prior to screening
   - No changes in diabetes medication within 8 weeks of screening

5. **Renal Function**
   - Estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73m² using the CKD-EPI equation

6. **Body Mass Index**
   - BMI between 22 and 40 kg/m² (inclusive)

7. **Informed Consent**
   - Willing and able to provide written informed consent
   - Able to comply with study procedures and visit schedule

---

## EXCLUSION CRITERIA

Patients meeting ANY of the following criteria are NOT eligible:

1. **Type 1 Diabetes**
   - History or current diagnosis of Type 1 Diabetes Mellitus
   - History of diabetic ketoacidosis (DKA)

2. **Pregnancy and Nursing**
   - Pregnant women
   - Nursing/lactating women
   - Women of childbearing potential not using adequate contraception

3. **Renal Impairment**
   - Severe renal impairment (eGFR < 30 mL/min/1.73m²)
   - History of renal transplant
   - Currently on dialysis

4. **Insulin Use**
   - Current use of insulin therapy
   - Use of insulin within 3 months prior to screening (except for acute illness)

5. **Cardiovascular Events**
   - Acute cardiovascular event within 6 months prior to screening:
     - Myocardial infarction
     - Stroke
     - Transient ischemic attack
     - Hospitalization for heart failure

6. **Liver Disease**
   - ALT or AST > 3x upper limit of normal (ULN)
   - History of chronic liver disease
   - History of hepatitis B or C

7. **Other Diabetes Medications**
   - Use of GLP-1 receptor agonists within 3 months of screening
   - Use of SGLT2 inhibitors within 3 months of screening
   - Use of thiazolidinediones within 3 months of screening

8. **Hypoglycemia Risk**
   - History of severe hypoglycemia (requiring third-party assistance) within 6 months
   - Impaired awareness of hypoglycemia

9. **Other Medical Conditions**
   - Active malignancy (except non-melanoma skin cancer)
   - Known HIV infection
   - Major surgery planned during the study period
   - Any condition that, in the investigator's opinion, would compromise patient safety

10. **Prior Participation**
    - Previous participation in this study
    - Participation in another clinical trial within 30 days of screening

---

## Study Duration
- Screening period: Up to 4 weeks
- Treatment period: 52 weeks
- Follow-up period: 4 weeks

## Primary Endpoint
Change from baseline in HbA1c at Week 26

## Secondary Endpoints
- Change in fasting plasma glucose
- Proportion of patients achieving HbA1c < 7%
- Change in body weight
- Safety and tolerability
